Medication info
Biatin Tablet 100 mg (Sitagliptin Hydrochloride Hydrate)

Biatin Tablet 100 mg (Sitagliptin Hydrochloride Hydrate)

Prescription medicationTablet
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›113.4mg / 1 tablet
Manufacturer / importer
Korea United Pharm., Co., Ltd.
Appearance
Orange, round, biconvex, film-coated tablet
Packaging
30 tablets/box [10 tablets/PTP×3EA]
Approval status
Active

MFDS item code 202000060 · Approved 2020.01.03 · Insurance code 644309410

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
This medication is administered at 100 mg once daily, either as monotherapy or in combination therapy. The maximum daily dose is 100 mg. This medication may be taken with or without food. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dose adjustment based on renal function is necessary, renal function should be assessed before treatment with this medication and periodically thereafter. 1. No dose adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is required in patients with moderate renal impairment (eGFR ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. For patients with moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2), administer 50 mg once daily. 4. For patients with severe renal impairment (eGFR ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (eGFR < 15 mL/min/1.73 m2), administer 25 mg once daily. This medication may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
Korea United Pharm., Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Difficulty in blood glucose control for patients with type 2 diabetes
View approved original text

This medication is used as a treatment to control blood glucose levels in patients with type 2 diabetes, and is used in conjunction with dietary and exercise therapy. It can be administered as monotherapy for patients receiving treatment for the first time, and if blood glucose control is difficult with monotherapy, it is combined with metformin. Additionally, if sufficient blood glucose control cannot be achieved with sulfonylurea, metformin, thiazolidinedione, or insulin monotherapy, this medication can be used in combination to enhance treatment efficacy. It can also be added if blood glucose control is difficult even with multiple medications. This medication helps with blood glucose management across various treatment stages, making it effective in the treatment of diabetes.

Dosage and Administration

Adult dosage

This medication is administered at 100 mg once daily, either as monotherapy or in combination therapy. The maximum daily dose is 100 mg. This medication may be taken with or without food. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dose adjustment based on renal function is necessary, renal function should be assessed before treatment with this medication and periodically thereafter. 1. No dose adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is required in patients with moderate renal impairment (eGFR ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. For patients with moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2), administer 50 mg once daily. 4. For patients with severe renal impairment (eGFR ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (eGFR < 15 mL/min/1.73 m2), administer 25 mg once daily. This medication may be administered regardless of the timing of dialysis.

Precautions

This medication can occasionally cause serious allergic reactions, so if symptoms such as skin rash, difficulty breathing, swelling of the face or neck occur within three months of administration, discontinue use immediately and seek medical attention. During the use of this medication, severe pancreatic inflammation known as pancreatitis may occur, so if abdominal pain, vomiting, or severe abdominal pain arise, inform your doctor immediately. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, and it should not be administered if there is an allergy to this medication or its components. Patients with reduced kidney function need to have the dosage of this medication adjusted, so they should undergo kidney function tests and take it according to their doctor's instructions. While taking this medication, side effects such as upper respiratory tract infections, nasopharyngitis, headache, diarrhea, nausea, and more may occur. When taken with other hypoglycemic agents or insulin, the risk of hypoglycemia may increase, so be careful for symptoms of hypoglycemia and adjust the dosage with the advice of a doctor as needed. Rare side effects such as arthralgia or skin blisters have been reported, so if severe joint pain or blisters or rashes appear on the skin, notify your doctor immediately. Pregnant or breastfeeding women are advised not to use this medication, and safety has not been established in children and adolescents under 18 years of age. Elderly patients may have reduced kidney function, so regular kidney function tests should be conducted before and during the use of this medication. In case of overdose, seek medical attention immediately for appropriate treatment, and this medication can be partially removed by hemodialysis, so dialysis treatment may be considered if necessary.

Side effects

  • Severe hypersensitivity reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • hypoglycemia
  • upper respiratory tract infections
  • nasopharyngitis
  • headache
  • diarrhea
Show 25 more
  • abdominal pain
  • nausea
  • peripheral edema
  • constipation
  • vomiting
  • arthralgia with severity and disability
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure
  • pneumonia
  • diabetes complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • dyspepsia
  • dizziness
  • increased serum triglycerides
  • gastritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air from entering, and it is recommended to keep it at room temperature between 1°C and 30°C. Proper storage helps maintain the efficacy of the medication.

Appearance and packaging

Appearance

Orange, round, biconvex, film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP×3EA]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.